Clinical outcomes for anti-CD19 CAR T cell (CTL019) products not meeting commercial release specifications
Sign Up to like & getrecommendations! Published in 2020 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2020.03.011
Abstract: Background & Aim Background: Tisagenlecleucel (CTL019) is approved for treatment of relapsed/refractory (r/r) aggressive B-cell lymphomas after second line therapy. Prior to CTL019 release for commercial use in the United States, the final manufactured, patient-specific… read more here.
Keywords: ctl019; release specifications; ctl019 products; cell ... See more keywords